Acura Pharma is setting up to Breakout after today's 23% gain.
ACURA PHARMACEUTICALS IN. (OTC ACUR) What a lovely trade this is setting up to be, everything is pointing to a breakout from a 1 year old channel of congestion, RSI, MON, MACD and Histogram are becoming bullish
and just like the price, entering a area of resistance. Because the stock has been so range bound for such a long time, any breakout will be amazing and fast, buys will be triggered and off it will go.
NOTEWORTHY ANNOUNCEMENT
www.benzinga.com/users/shanthi-rexaline
Acura Pharmaceuticals, Inc. (OTC: ACUR) announced a licensing, development and commercialization agreement with Abuse Deterrent Pharma – a special purpose company representing a consortium of investors, which will finance the company's operations and completion of the development of LTX-03 immediate-release tablets using Acura's patented LIMITx technology.
The investigational drug addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse.
The transaction is valued up to $21.3 million, not including royalties. The agreement also provides for Acura receiving royalties and potential sales-related milestones and AD Pharma retaining commercialization rights.
COMPANY PROFILE
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the US. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company has developed Aversion and Limitx technologies are intended to address methods of abuse associated with opioid analgesics whereas Impede technology is directed at minimizing the extraction and conversion of pseudoephedrine (PSE), into methamphetamine. Its product line includes OXAYDO which is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and other pipeline products.
and just like the price, entering a area of resistance. Because the stock has been so range bound for such a long time, any breakout will be amazing and fast, buys will be triggered and off it will go.
NOTEWORTHY ANNOUNCEMENT
www.benzinga.com/users/shanthi-rexaline
Acura Pharmaceuticals, Inc. (OTC: ACUR) announced a licensing, development and commercialization agreement with Abuse Deterrent Pharma – a special purpose company representing a consortium of investors, which will finance the company's operations and completion of the development of LTX-03 immediate-release tablets using Acura's patented LIMITx technology.
The investigational drug addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse.
The transaction is valued up to $21.3 million, not including royalties. The agreement also provides for Acura receiving royalties and potential sales-related milestones and AD Pharma retaining commercialization rights.
COMPANY PROFILE
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the US. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company has developed Aversion and Limitx technologies are intended to address methods of abuse associated with opioid analgesics whereas Impede technology is directed at minimizing the extraction and conversion of pseudoephedrine (PSE), into methamphetamine. Its product line includes OXAYDO which is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and other pipeline products.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media